In $11.6 Billion Buyout, Pfizer Acquires Biohaven and Suite of Migraine Meds

Pfizer has acquired Biohaven Pharmaceutical and its migraine drug Nurtec ODT (rimegepant sulfate), which is approved for both the prevention and treatment of episodic migraine in adults.
Source: Drug Industry Daily